Compare PROF & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PROF | OBIO |
|---|---|---|
| Founded | N/A | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.8M | 253.9M |
| IPO Year | 2017 | 2020 |
| Metric | PROF | OBIO |
|---|---|---|
| Price | $5.68 | $6.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $12.00 | ★ $14.25 |
| AVG Volume (30 Days) | 120.7K | ★ 386.0K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.89 | ★ 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | $16,098,000.00 | ★ $33,482,000.00 |
| Revenue This Year | $92.40 | N/A |
| Revenue Next Year | $64.10 | $12.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 50.73 | ★ 1169.22 |
| 52 Week Low | $3.92 | $2.20 |
| 52 Week High | $8.95 | $6.25 |
| Indicator | PROF | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 27.52 | 67.47 |
| Support Level | $4.97 | $3.87 |
| Resistance Level | $6.06 | N/A |
| Average True Range (ATR) | 0.35 | 0.35 |
| MACD | -0.10 | 0.06 |
| Stochastic Oscillator | 16.23 | 77.27 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.